SCHEMBL2560122

SCHEMBL2560122

O=C(Nc1ccc(-c2ccccc2)cc1)Oc1cnc(-n2cccn2)nc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PORCN Q9H237 4/20 0.42
HSP90AA1 P07900 1/20 0.41
EGLN1 Q9GZT9 2/20 0.41
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TBK1 Q9UHD2 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
FAAH O00519 2/20 0.36
NAMPT P43490 1/20 0.36
CYP2D6 P10635 2/20 0.35
CYP3A4 P08684 1/20 0.35
NTRK1 P04629 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575235 0.94 HSP90AA1 (0.46) HSP90AA1EGLN1MEN1KMT2AHTT
SCHEMBL2572995 0.87 EGLN1 (0.41) HSP90AA1EGLN1MEN1KMT2AMAPT
SCHEMBL2561208 0.87 MEN1 (0.53) EGLN1MEN1KMT2AMAPTHTT
SCHEMBL2560126 0.81 MEN1 (0.46) PORCNEGLN1MEN1KMT2AMAPT
SCHEMBL2575184 0.78 RAB9A (0.41) EGLN1MEN1KMT2AKDM4E
SCHEMBL2564810 0.77 EGLN1 (0.36) EGLN1MEN1KMT2ANPSR1KDM4E
SCHEMBL16005608 0.77 EGLN1 (0.37) EGLN1MEN1KMT2ANPSR1KDM4E
SCHEMBL2575239 0.76 TRPV1 (0.40) EGLN1MEN1KMT2AMAPTKDM4E
SCHEMBL2561739 0.75 EGLN1 (0.47) EGLN1MEN1KMT2AKDM4EALDH1A1
SCHEMBL2575436 0.74 ADORA2A (0.42) EGLN1ALDH1A1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560655-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2016-08-24 EP claimed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US claimed
EP-2560655-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2013-02-27 EP claimed
WO-2011133444-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO claimed
WO-2011130908-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO claimed
EP-2560655-B1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME (US) 2016-08-24 EP disclosed
EP-2560655-A1 SUBSTITUTED PYRIMIDINES Merck Sharp & Dohme Corp. (US) 2013-02-27 EP disclosed
US-20130018053-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME LLC 2013-01-17 US disclosed
WO-2011133444-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed
WO-2011130908-A1 SUBSTITUTED PYRIMIDINES MERCK SHARP & DOHME CORP. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018053-A1 SUBSTITUTED PYRIMIDINES HIF1AN, HIF1A, EGLN3 PORCN 4717/4885HSP90AA1 1387/4885EGLN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.